0001209191-20-030498.txt : 20200519 0001209191-20-030498.hdr.sgml : 20200519 20200519163524 ACCESSION NUMBER: 0001209191-20-030498 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200515 FILED AS OF DATE: 20200519 DATE AS OF CHANGE: 20200519 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kewalramani Reshma CENTRAL INDEX KEY: 0001735944 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 20894174 MAIL ADDRESS: STREET 1: C/O VERTEX PHARMACEUTICALS, INC. STREET 2: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-05-15 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001735944 Kewalramani Reshma C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 1 1 0 0 CEO & President Common Stock 2020-05-15 4 S 0 2 274.37 D 26723 D Common Stock 2020-05-15 4 S 0 6 276.40 D 26717 D Common Stock 2020-05-15 4 S 0 7 279.70 D 26710 D Common Stock 2020-05-15 4 S 0 9 280.47 D 26701 D Common Stock 2020-05-15 4 S 0 6 281.74 D 26695 D Common Stock 2020-05-15 4 S 0 4 282.74 D 26691 D Common Stock 2020-05-15 4 S 0 10 283.76 D 26681 D Common Stock 2020-05-15 4 S 0 27 286.07 D 26654 D Common Stock 2020-05-15 4 S 0 19 287.63 D 26635 D Common Stock 2020-05-15 4 S 0 9 288.37 D 26626 D Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $274.37 (range $274.03 to $274.71). Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $276.40 (range $275.85 to $276.75). Open market sales reported on this line occurred at a weighted average price of $279.70 (range $279.13 to $280.06). Open market sales reported on this line occurred at a weighted average price of $280.47 (range $280.16 to $280.73). Open market sales reported on this line occurred at a weighted average price of $281.74 (range $281.24 to $282.23). Open market sales reported on this line occurred at a weighted average price of $282.74 (range $282.46 to $283.35). Open market sales reported on this line occurred at a weighted average price of $286.07 (range $285.72 to $286.63). Open market sales reported on this line occurred at a weighted average price of $287.63 (range $287.18 to $288.10). Open market sales reported on this line occurred at a weighted average price of $288.37 (range $288.23 to $288.47). /s/ Sabrina Yohai, Attorney-in-Fact 2020-05-19